 CAMBRIDGE, Mass., Nov. 07, 2022 GLOBE NEWSWIRE -- Spero Therapeutics, Inc. Nasdaq: SPRO, a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant MDR bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline. 